凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物2007年半年度报告摘要

公告日期 2007-08-04
股票简称:华兰生物 股票代码:002007
证券代码:002007                               证券简称:华兰生物                           公告编号:2007-031

                              华兰生物工程股份有限公司2007年半年度报告摘要

    §1 重要提示
    1.1 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性负个别及连带责任。
    本半年度报告摘要摘自半年度报告全文,报告全文同时刊载于巨潮资讯网(www.cninfo.com.cn)。投资者欲了解详细内容,应当仔细阅读半年度报告全文。
    1.2 没有董事、监事、高级管理人员对半年度报告内容的真实性、准确性和完整性无法保证或存在异议。
    1.3 董事安颖女士因出差原因未能参加本次董事会,委托董事长安康先生出席并代为表决。
    1.4 公司半年度财务报告已经天健华证中洲(北京)会计师事务所有限公司审计并出具标准无保留意见的审计报告。
    1.5 公司负责人安康先生、主管会计工作负责人王启平先生及会计机构负责人桑莉女士声明:保证半年度报告中财务报告的真实、完整。
    §2 上市公司基本情况
    2.1 基本情况简介


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  股票简称                          华兰生物                                                                           
  股票代码                          002007                                                                             
  上市证券交易所                    深圳证券交易所                                                                     
                                    董事会秘书                                证券事务代表                             
  姓名                              范蓓                                      /                                        
  联系地址                          河南省新乡市华兰大道甲1号                 /                                        
  电话                              0373-3519901                              /                                        
  传真                              0373-3519911                              /                                        
  电子信箱                          hualan@hualanbio.com                      /                                        
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
2.2 主要财务数据和指标
    2.2.1 主要会计数据和财务指标
    单位:(人民币)元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
                                                本报告期末          上年度期末         本报告期末比上年度期末增减(%  
                                                                                       )                              
  总资产                                        900,087,359.07      816,570,601.51     10.23%                          
  所有者权益(或股东权益)                      607,306,897.68      555,725,915.60     9.28%                           
  每股净资产                                    3.357               3.686              -8.93%                          
                                                报告期(1-6月)    上年同期           本报告期比上年同期增减(%)    
  营业总收入                                    171,331,860.41      177,006,514.96     -3.21%                          
  营业利润                                      53,538,691.57       50,035,145.53      7.00%                           
  利润总额                                      53,324,807.84       47,793,144.12      11.57%                          
  净利润                                        51,580,982.08       40,528,262.77      27.27%                          
  扣除非经常性损益后的净利润                    51,740,129.93       41,073,075.61      25.97%                          
  基本每股收益                                  0.285               0.403              -29.28%                         
  稀释每股收益                                  0.285               0.403              -29.28%                         
  净资产收益率                                  8.49%               7.84%              0.65%                           
  经营活动产生的现金流量净额                    38,222,363.61       12,852,279.64      197.40%                         
  每股经营活动产生的现金流量净额                0.211               0.128              64.84%                          
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
2.2.2 非经常性损益项目
    √ 适用 □ 不适用
    单位:(人民币)元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  非经常性损益项目                                              金额                                                   
  非流动资产处置损益                                            0.00                                                   
  越权审批或无正式批文的税收返还、减免                          0.00                                                   
  计入当期损益的政府补助                                        0.00                                                   
  除上述各项之外的其他营业外收支净额                            -159,147.85                                            
  其他非经常性损益项目                                          0.00                                                   
  减:所得税影响数                                              0.00                                                   
  合计                                                          -159,147.85                                            
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
2.2.3 国内外会计准则差异
    □ 适用 √ 不适用
    §3 股本变动及股东情况
    3.1 股份变动情况表
    √ 适用 □ 不适用
    单位:股


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
                      本次变动前            本次变动增减(+,-)                                  本次变动后           
                      数量       比例       发行新股  送股       公积金转   其他       小计       数量       比例      
                                                                 股                                                    
  一、有限售条件股份  49,982,58  33.16%     0         0          9,996,516  0          9,996,516  59,979,09  33.16%    
                      0                                                                           6                    
  1、国家持股         0          0.00%      0         0          0          0          0          0          0.00%     
  2、国有法人持股     0          0.00%      0         0          0          0          0          0          0.00%     
  3、其他内资持股     36,662,58  24.32%     0                    7,332,516  0          7,332,516  43,995,09  24.32%    
                      0                                                                           6                    
  其中:境内非国有法  36,651,60  24.31%     0         0          7,330,320  0          7,330,320  43,981,92  24.31%    
  人持股              0                                                                           0                    
  境内自然人持股      10,980     0.01%      0         0          2,196      0          2,196      13,176     0.01%     
  4、外资持股         13,320,00  8.84%      0         0          2,664,000  0          2,664,000  15,984,00  8.84%     
                      0                                                                           0                    
  其中:境外法人持股  13,320,00  8.84%      0         0          2,664,000  0          2,664,000  15,984,00  8.84%     
                      0                                                                           0                    
  境外自然人持股      0          0.00%      0         0          0          0          0          0          0.00%     
  二、无限售条件股份  100,767,4  66.84%     0         0          20,153,48  0          20,153,48  120,920,9  66.84%    
                      20                                         4                     4          04                   
  1、人民币普通股     100,767,4  66.84%     0         0          20,153,48  0          20,153,48  120,920,9  66.84%    
                      20                                         4                     4          04                   
  2、境内上市的外资   0          0.00%      0         0          0          0          0          0          0.00%     
  股                                                                                                                   
  3、境外上市的外资   0          0.00%      0         0          0          0          0          0          0.00%     
  股                                                                                                                   
  4、其他             0          0.00%      0         0          0          0          0          0          0.00%     
  三、股份总数        150,750,0  100.00%    0         0          30,150,00  0          30,150,00  180,900,0  100.00%   
                      00                                         0                     0          00                   
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
3.2 前10名股东、前10名无限售条件股东持股情况表
    单位:股


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  股东总数                    3,996                                                                                    
  前10名股东持股情况                                                                                                   
  股东名称                    股东性质            持股比例   持股总数        持有有限售条件股份数  质押或冻结的股份数  
                                                                             量                    量                  
  新乡市华兰生物技术有限公司  境内非国有法人      18.48%     33,438,744      24,393,744                                
  新乡市金康生物科技开发有限  境内非国有法人      15.83%     28,633,176      19,588,176                                
  公司                                                                                                                 
  香港科康有限公司            境外法人            13.84%     25,029,000      15,984,000                                
  交通银行-汉兴证券投资基金  国有法人            4.52%      8,182,838       0                                         
  北京东方世辰生物技术有限公  境内非国有法人      4.43%      8,009,280       0                                         
  司                                                                                                                   
  汉盛证券投资基金            国有法人            3.04%      5,500,000       0                                         
  中国工商银行-汇添富成长焦  国有法人            2.81%      5,087,106       0                                         
  点股票型证券投资基金                                                                                                 
  中国人寿保险股份有限公司-  国有法人            2.39%      4,332,235       0                                         
  分红-个人分红-005L-FH002                                                                                            
  深                                                                                                                   
  中国工商银行-汇添富均衡增  国有法人            2.09%      3,781,857       0                                         
  长股票型证券投资基金                                                                                                 
  中国工商银行-安信证券投资  国有法人            1.99%      3,600,000       0                                         
  基金                                                                                                                 
  前10名无限售条件股东持股情况                                                                                         
  股东名称                                    持有无限售条件股份数量               股份种类                            
  新乡市华兰生物技术有限公司                  9,045,000                            人民币普通股                        
  新乡市金康生物科技开发有限公司              9,045,000                            人民币普通股                        
  香港科康有限公司                            9,045,000                            人民币普通股                        
  交通银行-汉兴证券投资基金                  8,182,838                            人民币普通股                        
  北京东方世辰生物技术有限公司                8,009,280                            人民币普通股                        
  汉盛证券投资基金                            5,500,000                            人民币普通股                        
  中国工商银行-汇添富成长焦点股票型证券投资  5,087,106                            人民币普通股                        
  基金                                                                                                                 
  中国人寿保险股份有限公司-分红-个人分红-0  4,332,235                            人民币普通股                        
  05L-FH002深                                                                                                          
  中国工商银行-汇添富均衡增长股票型证券投资  3,781,857                            人民币普通股                        
  基金                                                                                                                 
  中国工商银行-安信证券投资基金              3,600,000                            人民币普通股                        
  上述股东关联关系或一致行动  公司第一、二、三大股东实际控制人为本公司董事长安康先生;公司第五大股东东方世辰的股东之一 
  的说明                      安颖女士为公司实际控制人安康先生的妹妹,因此,上述股东之间存在关联关系,属于《上市公司股 
                              东持股变动信息披露管理办法》中规定的一致行动人;汉兴证券投资基金、汉盛证券投资基金同属于  
                              富国基金管理有限公司旗下基金,汇添富成长焦点股票型证券投资基金、汇添富均衡增长股票型证券  
                              投资基金同属于汇添富基金管理有限公司旗下基金,未知以上其他股东之间是否存在关联关系或者属 
                              于《上市公司股东持股变动信息披露管理办法》规定的一致行动人。                             
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
3.3 控股股东及实际控制人变更情况
    □ 适用 √ 不适用
    §4 董事、监事和高级管理人员情况
    4.1 董事、监事和高级管理人员持股变动
    √ 适用 □ 不适用


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  姓名         职务             年初持股数   本期增持股   本期减持股   期末持股数   变动原因                           
                                             份数量       份数量                                                       
  安康         董事长           12,240       2,448        0            14,688       资本公积金转增                     
  林小军       总经理           0            0            0            0                                               
  范蓓         董事会秘书       0            0            0            0                                               
  潘若文       副总经理         0            0            0            0                                               
  王启平       财务总监         2,400        360          600          2,160        二级市场卖出及资本公积金转增       
  安颖         董事             0            0            0            0                                               
  黄培堂       独立董事         0            0            0            0                                               
  李德富       独立董事         0            0            0            0                                               
  冯顺利       独立董事         0            0            0            0                                               
  马小伟       监事             0            0            0            0                                               
  张宝献       监事             0            0            0            0                                               
  陈磊山       监事             0            0            0            0                                               
  杨保平       监事             0            0            0            0                                               
  韩斌         监事             0            0            0            0                                               
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
上述人员持有本公司的股票期权及被授予的限制性股票数量
    □ 适用 √ 不适用
    §5 董事会报告
    5.1 主营业务分行业、产品情况表
    单位:(人民币)万元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  主营业务分行业情况                                                                                                   
  分行业或分产品         营业收入        营业成本        毛利率(%)    营业收入比上年  营业成本比上   毛利率比上年同  
                                                                        同期增减(%)   年同期增减(%  期增减(%)     
                                                                                        )                             
  血液制品               17,116.84       8,934.98        47.80%         -3.02%          -13.95%        6.63%           
  主营业务分产品情况                                                                                                   
  人血白蛋白             9,755.84        5,470.18        43.93%         -26.55%         -24.05%        -1.84%          
  静注丙球               4,462.55        1,598.49        64.18%         163.28%         29.49%         37.01%          
  其它                   2,898.45        1,866.31        35.61%         8.46%           -4.11%         8.45%           
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
其中:报告期内上市公司向控股股东及其子公司销售产品和提供劳务的关联交易总金额为0.00万元
    5.2 主营业务分地区情况
    单位:(人民币)万元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  地区                                              营业收入                          营业收入比上年增减(%)         
  华北                                              3,293.25                          6.15%                            
  华东                                              5,113.27                          -28.19%                          
  华南                                              2,301.70                          -15.29%                          
  华中                                              4,604.87                          51.40%                           
  西北                                              1,001.44                          -20.96%                          
  国外                                              599.94                            185.64%                          
  合计                                              17,116.84                         -3.02%                           
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
5.3 主营业务及其结构发生重大变化的原因说明
    □ 适用 √ 不适用
    5.4 主营业务盈利能力(毛利率)与上年相比发生重大变化的原因说明
    □ 适用 √ 不适用
    5.5 利润构成与上年度相比发生重大变化的原因分析
    √ 适用 □ 不适用


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  (1)营业税金及附加、管理费用较上年同期分别增长73,027.70元和6,426,448.22元,增幅达396.01%、64.04%,主要原因系本报告  
  期新增成立的合资子公司所致。(2)财务费用较上年同期增长1,413,524.91元,增幅181.69%,主要系上期取得财政贴息收入冲减财 
  务费用而本期无该类收入发生所致。(3)资产减值损失较上年同期增长1,301,295.62元,增幅532.51%,主要系控股子公司华兰生物 
  医药营销有限公司计提坏账损失所致。(4)营业外支出较上年同期减少2,168,170.38元,降幅90.94%,主要系上期清理固定资产所  
  致。(5)所得税费用较上年同期减少4,182,976.60元,降幅57.46%,主要系2006年所得税汇算多缴税款本报告期内冲抵所致。      
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
5.6 募集资金使用情况
    5.6.1 募集资金运用
    √ 适用 □ 不适用
    单位:(人民币)万元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  募集资金总额          32,923.80                   报告期内已使用募集资金总额     4,891.00                            
                                                    已累计使用募集资金总额         24,962.96                           
  承诺项目              是否已   原计划投  报告期   累计已   实际投资  报告期内实  项目建成时间   是否   是否  项目可  
                        变更项   入总额    内投入   投入金   进度(%   现的收益(  或预计建成时   符合   符合  行性是  
                        目                 金额     额       )        以利润总额  间             计划   预计  否发生  
                                                                       计算)                     进度   收益  重大变  
                                                                                                               化      
  年产100万套冻干人纤   否       1,327.00  0.00     1,327.0  100.00%   0.00        2004年06月30   是     否    否      
  维蛋白胶项目                                      0                              日                                  
  年产60吨病毒灭活人全  是       4,891.00  0.00     0.00     0.00%     0.00        -              -      -     否      
  血清项目                                                                                                             
  年产8000万单位静脉注  是       4,890.00  0.00     0.00     0.00%     0.00        -              -      -     否      
  射用人乙型肝炎免疫球                                                                                                 
  蛋白生产线高技术产业                                                                                                 
  化推进项目                                                                                                           
  年产40万支静脉注射用  否       4,354.00  0.00     1,111.6  25.53%    0.00        2007年12月31   是     是    否      
  人纤维蛋白原生产线高                              8                              日                                  
  技术产业化推进项目                                                                                                   
  年产1亿单位冻干人凝   否       4,908.00  0.00     4,908.0  100.00%   0.92        2006年12月31   是     否    否      
  血酶生产线高技术产业                              0                              日                                  
  化推进项目                                                                                                           
  年产70万支人破伤风免  否       4,649.00  0.00     4,649.0  100.00%   299.39      2006年12月31   是     是    否      
  疫球蛋白生产线高技术                              0                              日                                  
  产业化推进项目                                                                                                       
  年产12吨人血白蛋白生  否       4,950.20  0.00     4,974.0  100.42%   -198.01     2005年12月31   是     否    否      
  产线项目                                          0                              日                                  
  华兰生物工程技术研究  否       2,000.00  0.00     2,000.0  100.00%   0.00        2006年12月31   是     是    否      
  中心项目                                          0                              日                                  
  合计                  -        31,969.2  0.00     18,969.  -         102.30      -              -      -     -       
                                 0                  68                                                                 
  分项目说明未达到计划  1、年产100万套冻干人纤维蛋白胶项目由于目前国内医疗水平比较低,且该产品尚未纳入公费医疗范围,因 
  进度或预计收益的情况  此给公司产品的推广造成了一定的影响。2、年产12吨人血白蛋白生产线项目通过收购股权并增资的方式在  
  和原因                公司控股子公司华兰生物工程(苏州)有限公司实施,由于全国单采血浆站转制,原料血浆紧张等原因,目  
                        前该项未达到计划收益。3、年产1亿单位冻干人凝血酶生产线高技术产业化推进项目由于该项目于2006年年 
                        末完成并投入生产,产品市场开发需要一个过程;同时,生产产品的主原料血浆供应紧张,因此项目产品的 
                        收益未能达到预期。                                                                             
  项目可行性发生重大变  无                                                                                             
  化的情况说明                                                                                                         
  募集资金项目实施地点  华兰生物工程技术研究中心项目原计划在新乡市高新技术开发区建设,为更好地吸引人才,加强信息交流, 
  变更情况              经公司二届四次董事会审议通过,并提交公司2004年第一次临时股东大会通过改建到苏州高新技术开发区, 
                        已在相关媒体披露。                                                                             
  募集资金项目实施方式  年产12吨人血白蛋白项目原拟在新乡市高新技术开发区新征50亩地上实施,为缩短建设周期,较快实现收益 
  调整情况              ,达到合理布局,经公司二届四次董事会审议通过,并提交2004年第一次临时股东大会审议通过,变更为通 
                        过收购江苏华辰股权并增资的方式实施该项目,已在相关媒体披露。                                   
  募集资金项目先期投入  1、年产100万套外科用冻干人纤维蛋白胶项目经公司2002年第二次临时股东大会批准,计划总投资4827万元 
  及置换情况            ,其中国家提供贴息贷款3500万元,募集资金投入1327万元。该项目先期用银行贷款投入1327万元,2004年 
                        7月用募集资金归还上述先期投入的银行贷款1300万元,2005年1月从募集资金户转出27万元弥补先期垫付的 
                        流动资金。2、公司第二届董事会第六次会议和公司2004年度股东大会通过了加快实施年产1亿单位冻干人凝 
                        血酶生产线高技术产业化推进项目的议案(详见公司2005年2月26日在证券时报和巨潮资讯网上的相关公告  
                        ),公司用募集资金归还了前期银行借款2093.51万元。截止2005年底,募集资金已投入2,471.16万元,预  
                        计2006年将建成投入使用。3、公司第二届董事会第六次会议和公司2004年度股东大会通过了加快实施年产7 
                        0万支人破伤风免疫球蛋白生产线高技术产业化推进项目的议案(详见公司2005年2月26日在证券时报和巨潮 
                        资讯网上的相关公告),公司用募集资金归还了银行借款3846.50万元。4、2004年9月公司2004年第一次临  
                        时股东大会通过《关于公司新征建设用土地的议案》:在新乡市开发区本公司现有厂房的附近新征265亩土  
                        地。当时新征土地拟用于募集资金项目“注射用人乙型肝炎免疫球蛋白生产线高技术产业化推进项目”和“ 
                        年产40万支静脉注射用人纤维蛋白原生产线高技术产业化推进项目”及其他生产经营项目建设实施。公司于 
                        2004年9月、10月共预付土地款1,539.56万元,2005年度已开始进行前期筹备和基础设施建设,投资金额165 
                        .20万元,募集资金项目发生的征地费用和其他共同费用尚无法按项目分别核算投资金额,故2005年底暂时  
                        将上述两项目投资额合并列示。2006年度公司已取得新征土地的使用权证,根据土地使用权属证明按面积分 
                        摊后:归属于本公司之子公司华兰生物疫苗有限公司生产经营使用的购地款,由子公司自筹解决,原使用募 
                        集资金的购地款851.12万元由子公司退还,分别用于“年产50万支狂犬免疫球蛋白项目”(募集资金变更项 
                        目)和“年产40万支静脉注射用人纤维蛋白原生产线高技术产业化推进项目”2006年度的投资支出;原预付 
                        土地款1,539.56万元扣除由子公司华兰生物疫苗有限公司上述承担的款项851.12万元后,预付的688.44万元 
                        土地款平均分配计入上述两项募集资金项目投资额中。2005年度发生的项目前期筹备和基础设施建设投资金 
                        额165.20万元平均计入前述两项募集资金项目。                                                     
  用闲置募集资金暂时补  鉴于公司部分募集资金闲置,为降低公司的财务费用支出,2007年3月的二届二十次董事会及2007年4月2006 
  充流动资金情况        年度股东大会审议通过了《关于部分闲置募集资金补充流动资金的议案》,继续将募集资金补充流动资金。 
                        截至本报告期末,公司实际使用募集资金弥补流动资金金额为8000万元。                               
  项目实施出现募集资金  无                                                                                             
  结余的金额及原因                                                                                                     
  尚未使用的募集资金用  无                                                                                             
  途、去向以及募集资金                                                                                                 
  其他使用情况                                                                                                         
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
5.6.2 变更项目情况
    √ 适用 □ 不适用
    单位:(人民币)万元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  变更投资项目的资金总额         9,781.00                                                                              
  变更后的项目    对应的原承诺   变更后项  报告期   累计已   实际投资  报告期内   项目建成时间  是否   是否  变更后的  
                  项目           目拟投入  内投入   投入金   进度(%   实现的收   或预计建成时  符合   符合  项目可行  
                                 金额      金额     额       )        益(以利   间            计划   预计  性是否发  
                                                                       润总额计                 进度   收益  生重大变  
                                                                       算)                                  化        
  收购单采浆站项  年产60吨病毒   6,000.00  4,891.0  4,891.0  100.00%   0.00       2007年06月30  是     是    否        
  目              灭活人全血清             0        0                             日                                   
                  项目                                                                                                 
  年产50万支狂犬  年产8000万单   4,800.00  0.00     1,102.2  22.96%    0.00       2007年12月31  是     是    否        
  免疫球蛋白项目  位静脉注射用                      8                             日                                   
                  人乙型肝炎免                                                                                         
                  疫球蛋白生产                                                                                         
                  线高技术产业                                                                                         
                  化推进项目                                                                                           
  合计            -              10,800.0  4,891.0  5,993.2  -         0.00       -             -      -     -         
                                 0         0        8                                                                  
  分项目说明变更  1、年产60吨病毒灭活人全血清项目药品注册过程发生较大变化,该项目无法按原计划进行新药审评,为提高募集  
  原因及变更程序  资金使用效率,经公司2005年度股东大会审议通过,变更为收购单采血浆站项目。2、年产8000万单位静脉注射用  
                  人乙型肝炎免疫球蛋白生产线高技术产业化推进项目2005年药品注册法有部分修订,该项目临床观察时间延长,为 
                  提高募集资金使用效率,经公司2005年度股东大会审议通过,变更为年产50万支狂犬免疫球蛋白项目。           
  分项目说明未达  无                                                                                                   
  到计划进度或预                                                                                                       
  计收益的情况和                                                                                                       
  原因                                                                                                                 
  变更后的项目可  无                                                                                                   
  行性发生重大变                                                                                                       
  化的情况说明                                                                                                         
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
5.7 董事会下半年的经营计划修改计划
    □ 适用 √ 不适用
    5.8 对2007年前三季度经营业绩的预计
    单位:(人民币)元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  对2007年前三季度经营业绩的  净利润比上年同期增长幅度小于30%                                                          
  预计                                                                                                                 
  2006年前三季度的经营业绩    净利润(未按新会计准则调整)   64,126,289.91                                             
  业绩变动的原因说明          公司产品价格上涨及血浆综合利用率提高。                                                   
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
5.9 公司董事会对会计师事务所本报告期“非标准审计报告”的说明
    □ 适用 √ 不适用
    5.10 公司董事会对会计师事务所上年度“非标准审计报告”涉及事项的变化及处理情况的说明
    □ 适用 √ 不适用
    §6 重要事项
    6.1 收购、出售资产及资产重组
    6.1.1 收购资产
    √适用  □不适用
    1、报告期内,公司收购了12家单采血浆,已支付收购款5462.65万元。
    2、报告期内,公司通过竞拍的方式购得重庆益拓生物制品有限公司整体资产,共支付款项4360万元。
    6.1.2 出售资产
    □ 适用 √ 不适用
    6.1.3 自资产重组报告书或收购出售资产公告刊登后,该事项的进展情况及对报告期经营成果与财务状况的影响
    □ 适用 √ 不适用
    6.2 担保事项
    √ 适用 □ 不适用
    单位:(人民币)万元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  公司对外担保情况(不包括对子公司的担保)                                                                             
  担保对象名称       发生日期(协议签署日  担保金额    担保类型      担保期       是否履行完  是否为关联方担保(是或否 
                     )                                                           毕          )                       
  报告期内担保发生额合计                   0.00                                                                        
  报告期末担保余额合计(A)                0.00                                                                        
  公司对子公司的担保情况                                                                                               
  报告期内对子公司担保发生额合计           5,000.00                                                                    
  报告期末对子公司担保余额合计(B)        8,000.00                                                                    
  公司担保总额(包括对子公司的担保)                                                                                   
  担保总额(A+B)                          8,000.00                                                                    
  担保总额占净资产的比例                   13.17%                                                                      
  其中:                                                                                                               
  为股东、实际控制人及其关联方提供担保的   0.00                                                                        
  金额(C)                                                                                                            
  直接或间接为资产负债率超过70%的被担保对  0.00                                                                        
  象提供的担保金额(D)                                                                                                
  担保总额超过净资产50%部分的金额(E)    0.00                                                                        
  上述三项担保金额合计*(C+D+E)           0.00                                                                        
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
6.3 非经营性关联债权债务往来
    □ 适用 √ 不适用
    6.4 重大诉讼仲裁事项
    □ 适用 √ 不适用
    6.5 其他重大事项及其影响和解决方案的分析说明
    √ 适用 □ 不适用


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  报告期内公司开展投资者关系管理的具体情况:1、公司重视投资者关系管理工作,由公司董事长安康先生担任投资者关系管理负责  
  人,在安康先生的领导下公司证券部平时主要通过电话、传真、电子邮件等方式回答广大投资者的咨询,使其及时了解公司生产经营 
  情况。2、2007年4月3日,公司通过全景网投资者关系互动平台以网络远程方式举行了2006年度报告说明会,就公司年报业绩、未来  
  发展以及其他投资者关心的问题,与投资者进行了全面沟通交流。3、2007年4月13日,公司举办了一场投资者见面会,与三十余名基 
  金、券商、研究机构的代表进行了充分的沟通和交流。                                                                     
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
6.5.1 证券投资情况
    □ 适用 √ 不适用
    6.5.2 持有非上市金融企业和拟上市公司股权情况
    □ 适用 √ 不适用
    6.6 与日常经营相关的关联交易
    □ 适用 √ 不适用
    §7 财务报告
    7.1 审计意见


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  财务报告                  □未经审计√审计                                                                           
  审计报告                  √标准审计报告□非标准审计报告                                                             
  审计报告正文                                                                                                         
  审计报告天健华证中洲审(2007)GF字第060008号华兰生物工程股份有限公司全体股东:我们审计了后附的华兰生物工程股份有限公 
  司(以下简称贵公司)财务报表,包括2007年6月30日的资产负债表和合并资产负债表,2007年1-6月的利润表和合并利润表、现金流量 
  表和合并现金流量表、所有者权益变动表和合并所有者权益变动表以及财务报表附注。一、_管理层对财务报表的责任按照《企业会  
  计准则》的规定编制财务报表是贵公司管理层的责任。这种责任包括:(1)设计、实施和维护与财务报表编制相关的内部控制,以  
  使财务报表不存在由于舞弊或错误而导致的重大错报;(2)选择和运用恰当的会计政策;(3)作出合理的会计估计。二、_注册会  
  计师的责任我们的责任是在实施审计工作的基础上对财务报表发表审计意见。我们按照中国注册会计师审计准则的规定执行了审计工 
  作。中国注册会计师审计准则要求我们遵守职业道德规范,计划和实施审计工作以对财务报表是否不存在重大错报获取合理保证。审 
  计工作涉及实施审计程序,以获取有关财务报表金额和披露的审计证据。选择的审计程序取决于注册会计师的判断,包括对由于舞弊 
  或错误导致的财务报表重大错报风险的评估。在进行风险评估时,我们考虑与财务报表编制相关的内部控制,以设计恰当的审计程序 
  ,但目的并非对内部控制的有效性发表意见。审计工作还包括评价管理层选用会计政策的恰当性和作出会计估计的合理性,以及评价 
  财务报表的总体列报。我们相信,我们获取的审计证据是充分、适当的,为发表审计意见提供了基础。三、_审计意见我们认为,贵  
  公司财务报表已经按照《企业会计准则》的规定编制,在所有重大方面公允反映了贵公司2007年6月30日的财务状况以及2007年1-6月 
  的经营成果和现金流量。                                                                                               
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
7.2 财务报表
    7.2.1 资产负债表
    编制单位:华兰生物工程股份有限公司                    2007年06月30日                    单位:(人民币)元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目                           期末数                                     期初数                                     
                                 合并                 母公司                合并                  母公司               
  流动资产:                                                                                                           
  货币资金                       141,988,805.70       59,987,776.01         201,587,646.13        154,961,131.08       
  结算备付金                                                                                                           
  拆出资金                                                                                                             
  交易性金融资产                                                                                                       
  应收票据                       5,823,331.17         5,623,331.17          13,536,268.78         13,086,268.78        
  应收账款                       50,194,707.74        28,531,855.84         38,000,993.44         36,284,704.44        
  预付款项                       177,261,984.74       186,117,417.33        145,447,985.95        164,054,907.82       
  应收保费                                                                                                             
  应收分保账款                                                                                                         
  应收分保合同准备金                                                                                                   
  应收利息                                                                                                             
  其他应收款                     19,601,700.22        101,957,928.37        4,076,529.14          18,881,600.99        
  买入返售金融资产                                                                                                     
  存货                           98,426,388.84        81,213,353.28         81,081,622.68         73,165,475.45        
  一年内到期的非流动资产                                                                                               
  其他流动资产                                                              55,312.45             55,312.45            
  流动资产合计                   493,296,918.41       463,431,662.00        483,786,358.57        460,489,401.01       
  非流动资产:                                                                                                         
  发放贷款及垫款                                                                                                       
  可供出售金融资产                                                                                                     
  持有至到期投资                                                                                                       
  长期应收款                                                                                                           
  长期股权投资                                        160,198,885.39                              105,572,385.39       
  投资性房地产                                                                                                         
  固定资产                       245,021,330.64       129,935,238.41        218,094,238.40        120,400,018.30       
  在建工程                       103,876,277.09       25,222,907.13         84,159,723.15         19,483,641.01        
  工程物资                       370,410.40                                 370,410.40                                 
  固定资产清理                                                                                                         
  生产性生物资产                                                                                                       
  油气资产                                                                                                             
  无形资产                       56,661,158.50        17,130,789.17         29,273,632.82         9,991,933.85         
  开发支出                                                                                                             
  商誉                                                                                                                 
  长期待摊费用                                                              284,341.42                                 
  递延所得税资产                 861,264.03           522,436.89            601,896.75            581,584.29           
  其他非流动资产                                                                                                       
  非流动资产合计                 406,790,440.66       333,010,256.99        332,784,242.94        256,029,562.84       
  资产总计                       900,087,359.07       796,441,918.99        816,570,601.51        716,518,963.85       
  流动负债:                                                                                                           
  短期借款                       140,000,000.00       110,000,000.00        140,000,000.00        80,000,000.00        
  向中央银行借款                                                                                                       
  吸收存款及同业存放                                                                                                   
  拆入资金                                                                                                             
  交易性金融负债                                                                                                       
  应付票据                                                                  4,866,301.68          4,866,301.68         
  应付账款                       39,501,774.92        36,731,174.78         41,205,282.12         34,669,518.53        
  预收款项                       3,579,551.34         3,168,031.34          1,359,803.84          1,278,503.84         
  卖出回购金融资产款                                                                                                   
  应付手续费及佣金                                                                                                     
  应付职工薪酬                   11,148,534.87        10,757,178.85         13,383,390.18         13,382,390.18        
  应交税费                       3,618,307.82         2,587,933.76          5,166,505.66          5,009,656.97         
  应付利息                                                                                                             
  其他应付款                     8,967,336.20         15,650,039.63         17,546,032.75         17,446,677.05        
  应付分保账款                                                                                                         
  保险合同准备金                                                                                                       
  代理买卖证券款                                                                                                       
  代理承销证券款                                                                                                       
  一年内到期的非流动负债                                                                                               
  其他流动负债                                                                                                         
  流动负债合计                   206,815,505.15       178,894,358.36        223,527,316.23        156,653,048.25       
  非流动负债:                                                                                                         
  长期借款                       50,000,000.00                                                                         
  应付债券                                                                                                             
  长期应付款                                                                                                           
  专项应付款                     4,140,000.00         4,140,000.00          4,140,000.00          4,140,000.00         
  预计负债                                                                                                             
  递延所得税负债                                                                                                       
  其他非流动负债                                                                                                       
  非流动负债合计                 54,140,000.00        4,140,000.00          4,140,000.00          4,140,000.00         
  负债合计                       260,955,505.15       183,034,358.36        227,667,316.23        160,793,048.25       
  所有者权益(或股东权益):                                                                                           
  实收资本(或股本)             180,900,000.00       180,900,000.00        150,750,000.00        150,750,000.00       
  资本公积                       196,371,732.03       196,371,732.03        226,521,732.03        226,521,732.03       
  减:库存股                                                                                                           
  盈余公积                       34,458,182.22        34,458,182.22         34,458,182.22         34,458,182.22        
  一般风险准备                                                                                                         
  未分配利润                     195,576,983.43       201,677,646.38        143,996,001.35        143,996,001.35       
  外币报表折算差额                                                                                                     
  归属于母公司所有者权益合计     607,306,897.68       613,407,560.63        555,725,915.60        555,725,915.60       
  少数股东权益                   31,824,956.24                              33,177,369.68                              
  所有者权益合计                 639,131,853.92       613,407,560.63        588,903,285.28        555,725,915.60       
  负债和所有者权益总计           900,087,359.07       796,441,918.99        816,570,601.51        716,518,963.85       
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
7.2.2 利润表
    编制单位:华兰生物工程股份有限公司                     2007年1-6月                     单位:(人民币)元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目                           本期                                       上年同期                                   
                                 合并                 母公司                合并                  母公司               
  一、营业总收入                 171,331,860.41       163,273,944.13        177,006,514.96        163,407,240.04       
  其中:营业收入                                                                                                       
  利息收入                                                                                                             
  已赚保费                                                                                                             
  手续费及佣金收入                                                                                                     
  二、营业总成本                 117,793,168.84       102,708,988.91        126,971,369.43        113,411,256.28       
  其中:营业成本                 89,439,633.53        83,296,425.49         104,374,716.06        92,698,930.68        
  利息支出                                                                                                             
  手续费及佣金支出                                                                                                     
  退保金                                                                                                               
  赔付支出净额                                                                                                         
  提取保险合同准备金净额                                                                                               
  保单红利支出                                                                                                         
  分保费用                                                                                                             
  营业税金及附加                 91,468.69                                  18,440.99                                  
  销售费用                       9,618,958.05         9,613,890.78          13,076,372.56         12,972,552.56        
  管理费用                       16,461,890.46        9,973,320.93          10,035,442.24         8,835,894.18         
  财务费用                       63,553.09            -156,860.76           -777,971.82           -1,349,887.50        
  资产减值损失                   1,545,665.02         -17,787.53            244,369.40            253,766.36           
  加:公允价值变动收益(损失以                                                                                         
  “-”号填列)                                                                                                        
  投资收益(损失以“-”号填列)                                                                   -19,335.25           
  其中:对联营企业和合营企业的                                                                                         
  投资收益                                                                                                             
  汇兑收益(损失以“-”号填列)                                                                                        
  三、营业利润(亏损以“-”号填  53,538,691.57        60,564,955.22         50,035,145.53         49,976,648.51        
  列)                                                                                                                 
  加:营业外收入                 2,159.12                                   142,211.82            142,211.82           
  减:营业外支出                 216,042.85           161,799.56            2,384,213.23          2,384,213.23         
  其中:非流动资产处置损失                                                  2,161,168.10          2,161,168.10         
  四、利润总额(亏损总额以“-”  53,324,807.84        60,403,155.66         47,793,144.12         47,734,647.10        
  号填列)                                                                                                             
  减:所得税费用                 3,096,239.20         2,721,510.63          7,279,215.80          7,206,384.33         
  五、净利润(净亏损以“-”号填  50,228,568.64        57,681,645.03         40,513,928.32         40,528,262.77        
  列)                                                                                                                 
  归属于母公司所有者的净利润     51,580,982.08        57,681,645.03         40,528,262.77         40,528,262.77        
  少数股东损益                   -1,352,413.44                              -14,334.45                                 
  六、每股收益:                                                                                                       
  (一)基本每股收益             0.285                                      0.403                                      
  (二)稀释每股收益             0.285                                      0.403                                      
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
7.2.3 现金流量表
    编制单位:华兰生物工程股份有限公司                     2007年1-6月                     单位:(人民币)元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目                           本期                                       上年同期                                   
                                 合并                 母公司                合并                  母公司               
  一、经营活动产生的现金流量:                                                                                         
  销售商品、提供劳务收到的现金   200,501,217.55       207,483,151.31        207,769,323.36        189,481,689.13       
  客户存款和同业存放款项净增加                                                                                         
  额                                                                                                                   
  向中央银行借款净增加额                                                                                               
  向其他金融机构拆入资金净增加                                                                                         
  额                                                                                                                   
  收到原保险合同保费取得的现金                                                                                         
  收到再保险业务现金净额                                                                                               
  保户储金及投资款净增加额                                                                                             
  处置交易性金融资产净增加额                                                                                           
  收取利息、手续费及佣金的现金                                                                                         
  拆入资金净增加额                                                                                                     
  回购业务资金净增加额                                                                                                 
  收到的税费返还                                                            1,185,723.57                               
  收到其他与经营活动有关的现金   20,841,933.32        184,062.02            2,354,844.54          2,246,882.99         
  经营活动现金流入小计           221,343,150.87       207,667,213.33        211,309,891.47        191,728,572.12       
  购买商品、接受劳务支付的现金   81,570,841.20        74,889,066.02         136,449,532.17        128,063,602.16       
  客户贷款及垫款净增加额                                                                                               
  存放中央银行和同业款项净增加                                                                                         
  额                                                                                                                   
  支付原保险合同赔付款项的现金                                                                                         
  支付利息、手续费及佣金的现金                                                                                         
  支付保单红利的现金                                                                                                   
  支付给职工以及为职工支付的现   20,831,016.15        17,306,887.70         8,526,947.21          7,753,513.40         
  金                                                                                                                   
  支付的各项税费                 26,002,844.98        23,419,696.65         29,655,696.45         28,017,640.29        
  支付其他与经营活动有关的现金   54,716,084.93        41,640,103.79         23,825,436.00         19,433,859.70        
  经营活动现金流出小计           183,120,787.26       157,255,754.16        198,457,611.83        183,268,615.55       
  经营活动产生的现金流量净额     38,222,363.61        50,411,459.17         12,852,279.64         8,459,956.57         
  二、投资活动产生的现金流量:                                                                                         
  收回投资收到的现金                                                                                                   
  取得投资收益收到的现金                                                                                               
  处置固定资产、无形资产和其他                                                                                         
  长期资产收回的现金净额                                                                                               
  处置子公司及其他营业单位收到                                              81,500.00             81,500.00            
  的现金净额                                                                                                           
  收到其他与投资活动有关的现金                                                                                         
  投资活动现金流入小计                                                      81,500.00             81,500.00            
  购建固定资产、无形资产和其他   99,541,322.52        25,379,197.72         41,903,495.19         37,726,046.10        
  长期资产支付的现金                                                                                                   
  投资支付的现金                                      54,626,500.00         24,225,000.00         24,225,000.00        
  质押贷款净增加额                                                                                                     
  取得子公司及其他营业单位支付                                                                                         
  的现金净额                                                                                                           
  支付其他与投资活动有关的现金   43,600,000.00        93,600,000.00         10,344,770.00                              
  投资活动现金流出小计           143,141,322.52       173,605,697.72        76,473,265.19         61,951,046.10        
  投资活动产生的现金流量净额     -143,141,322.52      -173,605,697.72       -76,391,765.19        -61,869,546.10       
  三、筹资活动产生的现金流量:                                                                                         
  吸收投资收到的现金                                                                                                   
  其中:子公司吸收少数股东投资                                                                                         
  收到的现金                                                                                                           
  取得借款收到的现金             115,000,000.00       65,000,000.00         85,000,000.00         55,000,000.00        
  发行债券收到的现金                                                                                                   
  收到其他与筹资活动有关的现金                                                                                         
  筹资活动现金流入小计           115,000,000.00       65,000,000.00         85,000,000.00         55,000,000.00        
  偿还债务支付的现金             65,000,000.00        35,000,000.00         24,000,000.00                              
  分配股利、利润或偿付利息支付   4,589,063.75         1,688,298.75          28,374,998.75         27,593,956.75        
  的现金                                                                                                               
  其中:子公司支付给少数股东的                                                                                         
  股利、利润                                                                                                           
  支付其他与筹资活动有关的现金                                                                                         
  筹资活动现金流出小计           69,589,063.75        36,688,298.75         52,374,998.75         27,593,956.75        
  筹资活动产生的现金流量净额     45,410,936.25        28,311,701.25         32,625,001.25         27,406,043.25        
  四、汇率变动对现金及现金等价   -90,817.77           -90,817.77            -20,066.54            -20,066.54           
  物的影响                                                                                                             
  五、现金及现金等价物净增加额   -59,598,840.43       -94,973,355.07        -30,934,550.84        -26,023,612.82       
  加:期初现金及现金等价物余额   197,698,859.34       154,961,131.08        199,053,202.77        152,651,188.91       
  六、期末现金及现金等价物余额   138,100,018.91       59,987,776.01         168,118,651.93        126,627,576.09       
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
7.2.4 所有者权益变动表
    编制单位:华兰生物工程股份有限公司                                          2007年06月30日                                          单位:(人民币)元


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  项目              本期金额                                          上年金额                                         
                    归属于母公司所有者权益                 少数  所   归属于母公司所有者权益                 少   所有 
                    实收  资   减:  盈余  一   未分  其   股东  有   实收  资   减:  盈   一般  未   其他  数   者权 
                    资本  本   库存  公积  般   配利  他   权益  者   资本  本   库存  余   风险  分         股   益合 
                    (或  公   股          风   润               权   (或  公   股    公   准备  配         东   计   
                    股本  积               险                    益   股本  积         积         利         权        
                    )                     准                    合   )                          润         益        
                                           备                    计                                                    
  一、上年年末余额  150,  226        34,4       143,       33,1  588  100,  276        26,        123        24,  551, 
                    750,  ,52        58,1       996,       77,3  ,90  500,  ,62        558        ,01        571  263, 
                    000.  1,7        82.2       001.       69.6  3,2  000.  0,8        ,06        2,4        ,86  276. 
                    00    32.        2          35         8     85.  00    68.        5.8        79.        2.7  65   
                          03                                     28         90         3          21         1         
  加:会计政策变更                                                                                                     
  前期差错更正                                                                                                         
  二、本年年初余额  150,  226        34,4       143,       33,1  588  100,  276        26,        123        24,  551, 
                    750,  ,52        58,1       996,       77,3  ,90  500,  ,62        558        ,01        571  263, 
                    000.  1,7        82.2       001.       69.6  3,2  000.  0,8        ,06        2,4        ,86  276. 
                    00    32.        2          35         8     85.  00    68.        5.8        79.        2.7  65   
                          03                                     28         90         3          21         1         
  三、本年增减变动  30,1  -30                   51,5       -1,3  50,                              -9,        -14  -9,7 
  金额(减少以“-   50,0  ,15                   80,9       52,4  228                              721        ,33  36,0 
  ”号填列)        00.0  0,0                   82.0       13.4  ,56                              ,73        4.4  71.6 
                    0     00.                   8          4     8.6                              7.2        5    8    
                          00                                     4                                3                    
  (一)净利润                                  51,5       -1,3  50,                              40,        -14  40,5 
                                                80,9       52,4  228                              528        ,33  13,9 
                                                82.0       13.4  ,56                              ,26        4.4  28.3 
                                                8          4     8.6                              2.7        5    2    
                                                                 4                                7                    
  (二)直接计入所                                                                                                     
  有者权益的利得和                                                                                                     
  损失                                                                                                                 
  1.可供出售金融                                                                                                      
  资产公允价值变动                                                                                                     
  净额                                                                                                                 
  2.权益法下被投                                                                                                      
  资单位其他所有者                                                                                                     
  权益变动的影响                                                                                                       
  3.与计入所有者                                                                                                      
  权益项目相关的所                                                                                                     
  得税影响                                                                                                             
  4.其他                                                                                                              
  上述(一)和(二                              51,5       -1,3  50,                              40,        -14  40,5 
  )小计                                        80,9       52,4  228                              528        ,33  13,9 
                                                82.0       13.4  ,56                              ,26        4.4  28.3 
                                                8          4     8.6                              2.7        5    2    
                                                                 4                                7                    
  (三)所有者投入                                                                                                     
  和减少资本                                                                                                           
  1.所有者投入资本                                                                                                     
  2.股份支付计入                                                                                                      
  所有者权益的金额                                                                                                     
  3.其他                                                                                                              
  (四)利润分配                                                                                  -50             -50, 
                                                                                                  ,25             250, 
                                                                                                  0,0             000. 
                                                                                                  00.             00   
                                                                                                  00                   
  1.提取盈余公积                                                                                                      
  2.提取一般风险准                                                                                -50             -50, 
  备                                                                                              ,25             250, 
                                                                                                  0,0             000. 
                                                                                                  00.             00   
                                                                                                  00                   
  3.对所有者(或                                                                                                      
  股东)的分配                                                                                                         
  4.其他                                                                                                              
  (五)所有者权益  30,1  -30                                                                                          
  内部结转          50,0  ,15                                                                                          
                    00.0  0,0                                                                                          
                    0     00.                                                                                          
                          00                                                                                           
  1.资本公积转增   30,1  -30                                                                                          
  资本(或股本)    50,0  ,15                                                                                          
                    00.0  0,0                                                                                          
                    0     00.                                                                                          
                          00                                                                                           
  2.盈余公积转增                                                                                                      
  资本(或股本)                                                                                                       
  3.盈余公积弥补                                                                                                      
  亏损                                                                                                                 
  4.其他                                                                                                              
  四、本期期末余额  180,  196        34,4       195,       31,8  639  100,  276        26,        113        24,  541, 
                    900,  ,37        58,1       576,       24,9  ,13  500,  ,62        558        ,29        557  527, 
                    000.  1,7        82.2       983.       56.2  1,8  000.  0,8        ,06        0,7        ,52  204. 
                    00    32.        2          43         4     53.  00    68.        5.8        41.        8.2  97   
                          03                                     92         90         3          98         6         
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
7.3 报表附注
    7.3.1 如果出现会计政策、会计估计变更或会计差错更正的,说明有关内容、原因及影响数


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  一、会计政策变更2007年1月1日起,公司开始执行财政部“财会[2006]3号”文发布的《企业会计准则-基本准则》和其他各项具体会 
  计准则的规定(简称新准则),根据新准则规定,高速事项如下:(1)、所得税公司2006年12月31日前按原企业会计准则和《企业  
  会计制度》(简称原制度)会计政策对所得税采用应付税款法进行核算,根据新准则《企业会计准则第18号-所得税》的规定,公司  
  所得税的核算由应付税款法改变为资产负债表债务法。公司根据因计提的坏账准备、应付职工薪酬及长期股权投资等的账面价值与计 
  税基础的差额确认增加递延所得税资产601,896,76元,同时增加了净利润及股东权益,其中归属于母公司的净利润及股东权益597,83 
  4.26元。(2)、少数股东权益公司2006年12月31日按原制度编制的合并报表中少数股东权益33,177,369.68元未在股东权益中列示, 
  根据新准则相关规定将少数股东权益调增股东权益33,177,369.68元(单独列示)。二、公司本期无重大会计估计变更和会计差错更  
  正事项。                                                                                                             
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
7.3.2 如果财务报表合并范围发生重大变化的,说明原因及影响数
    √ 适用 □ 不适用


━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
  都安华兰单采血浆有限公司、陆川华兰单采血浆有限公司、贺州华兰单采血浆有限公司、华兰生物(独山)单采血浆有限公司、华兰 
  生物(龙里)单采血浆有限公司、华兰生物(罗甸)单采血浆有限公司、华兰生物(惠水)单采血浆有限公司、华兰生物(瓮安)单 
  采血浆有限公司、华兰生物(长顺)单采血浆有限公司九个单采血浆有限公司系公司本报告期新成立的全资子公司,本期将上述九公 
  司新增纳入合并报表范围。本期新增合并报表公司的财务状况和经营成果汇总如下:主要财务状况2007年6月30日主要经营成果2007  
  年1-6月流动资产50,309,045.39主营业务收入9,329,780.79固定资产19,986,090.88营业利润-2,025,856.90无形资产20,452,317.55  
  利润总额-2,074,947.78递延所得税资产93.71所得税70,548.09资产合计90,747,547.53净利润-2,145,495.87流动负债38,266,543.40 
  长期负债所有者权益52,481,004.13负债及所有者权益合计90,747,547.53                                                     
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
7.3.3 如果被出具非标准无保留意见,列示涉及事项的有关附注
      
    
数据加载中...
prevnext
手机查看股票